Vesicle-mediated mitochondrial clearance underlies an actionable metabolic vulnerability in triple-negative breast cancer

Jody Vykoukal,Yihui Chen,Monica J. Hong,Mingxin Zuo,Hansini Krishna,Hiroyuki Katayama,Ehsan Irajizad,Ranran Wu,Ricardo A. León-Letelier,Jennifer B. Dennison,Angelica M. Gutierrez,Adriana Paulucci-Holthauzen,Timothy C. Thompson,Leona Rusling,Yining Cai,Fu Chung Hsiao,Soyoung Park,Banu Arun,Samir Hanash,Johannes F. Fahrmann
DOI: https://doi.org/10.1101/2024.04.04.587899
2024-04-04
Abstract:Selective autophagy of mitochondria is known to promote survival and progression of cancer cells in various malignancies including triple-negative breast cancer (TNBC). Here, we aimed to identify the essential metabolic adaptations that support mitochondrial quality control with the goal to uncover actionable metabolic vulnerabilities with therapeutic potential. Using an integrated approach of proteomics and untargeted and stable-isotope resolved metabolomics, coupled with functional experimental analyses, we define an alternative mechanism to mitophagy enabled by an onco-metabolic program of heightened extracellular sphingomyelin salvaging in TNBC that facilitates extracellular vesicle (EV)-mediated intracellular clearance of mitochondrial damage. Targeting of the cancer cell sphingolipid onco-metabolic pathway via repurposing of eliglustat, a selective small molecule inhibitor of glucosylceramide synthase (UGCG), resulted in ceramide-induced lethal mitophagy and attenuated tumor growth and prolonged overall survival at clinically achievable doses in an orthotopic syngeneic mouse model of TNBC. Our study defines a mechanism of aberrant sphingolipid metabolism that underlies an actionable metabolic vulnerability for anti-cancer treatment.
Cancer Biology
What problem does this paper attempt to address?
The paper mainly discusses a new mechanism of impaired mitochondrial clearance in triple-negative breast cancer (TNBC). The study found that TNBC cells promote intracellular clearance of mitochondria damaged by extracellular vesicles (EVs) mediated through the enhancement of extracellular phospholipid recycling and reuse. This provides an alternative way to maintain mitochondrial quality control in TNBC, other than mitochondrial autophagy (mitophagy). Through comprehensive analysis of proteomics, untargeted and stable isotope-resolved metabolomics, as well as experimental functional analysis, the researchers identified the role of abnormal phospholipid metabolism in TNBC and revealed its potential as an actionable metabolic vulnerability for anti-tumor therapy. The study also demonstrated that eliglustat, a small molecule inhibitor of sphingolipid tumor metabolism pathway (a selective glucosylceramide synthase inhibitor), induces lethal mitochondrial autophagy. This slows tumor growth and prolongs survival in vitro and in in situ xenograft models of TNBC. The researchers observed the effects of different doses of eliglustat in reducing tumor growth and improving survival, with relatively minor impacts on healthy tissues during treatment. Furthermore, the research involved changes in mitochondrial morphology and function in TNBC cells, including the expression of mitochondria autophagy-related genes and regulation of mitochondrial dynamics, and how they influence disease progression. Through analysis of breast cancer cell lines and clinical samples, the authors emphasized the importance of mitochondrial quality control metabolic adaptability in cancer development, and proposed this adaptability as a potential target for anti-tumor therapy. Overall, this paper addresses a new mechanism of impaired mitochondrial clearance in TNBC and how to utilize this mechanism for the development of new treatment strategies.